Cargando…
Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial
OBJECTIVES: Tissue hypoxia is the main cause of multi-organ dysfunction in sepsis. However, effective pharmacological treatments to combat sepsis-induced tissue hypoxia are not available. Emerging experimental and clinical evidence reveals an evolutionary conserved action of thyroid hormone (TH) to...
Autores principales: | Pantos, Constantinos, Kostopanagiotou, Georgia, Armaganidis, Apostolos, Trikas, Athanasios, Tseti, Ioulia, Mourouzis, Iordanis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316579/ https://www.ncbi.nlm.nih.gov/pubmed/32586399 http://dx.doi.org/10.1186/s13063-020-04474-0 |
Ejemplares similares
-
Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial
por: Pantos, Constantinos, et al.
Publicado: (2020) -
Triiodothyronine prevents tissue hypoxia in experimental sepsis: potential therapeutic implications
por: Mourouzis, Iordanis S., et al.
Publicado: (2021) -
Effects of Thyroid Hormone on Tissue Hypoxia: Relevance to Sepsis Therapy
por: Lourbopoulos, Athanasios I., et al.
Publicado: (2021) -
The Potential of Thyroid Hormone Therapy in Severe COVID-19: Rationale and Preliminary Evidence
por: Mourouzis, Iordanis, et al.
Publicado: (2022) -
The Emerging Role of TRα1 in Cardiac Repair: Potential Therapeutic Implications
por: Pantos, Constantinos, et al.
Publicado: (2014)